UCBJF logo

UCBJF UCB S.A.

Other OTC · Medical - Pharmaceuticals · Healthcare

$254.59
-8.50 (-3.23%)

UCB S.A. is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for individuals affected by neurological and immunological disorders. Its extensive portfolio of marketed products includes Cimzia, indicated for various inflammatory TNF-mediated diseases such as Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid…

Market Cap: $48.46Bwww.ucb.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

120
120
Aug 11Aug 11

Quote

Day Range
$254.59 – $259.59
52-Week Range
$219.50 – $345.39
Volume
$1.00
Market Cap
$48.46B
50-Day Avg
$287.26
200-Day Avg
$292.01
Prev Close
$263.09
Open
$254.59

Valuation & Ratios

P/E Ratio
30.47
EPS
$8.20
P/B Ratio
4.37
P/S Ratio
6.14
Debt/Equity
0.21
Current Ratio
1.38
Dividend Yield
+0.6%
Gross Margin
+74.3%

Returns & Efficiency

Return on Equity
+14.3%
Return on Assets
+8.6%
FCF Yield
+4.0%
EV/EBITDA
18.42

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$7.74B$1.56B$8.20
2024$6.15B$1.06B$5.61
2023$5.25B$343.00M$1.81
2022$5.52B$418.00M$2.20
2021$5.78B$1.06B$5.60

Social Signal Score

70
5d
70
1 mentions
30d
70
1 mentions
60d
70
1 mentions
90d
70
1 mentions
news: 1

Earnings

Thu, Feb 25(in 6 months)

Consensus estimate $6.03 per share

3of 7 quarters beat consensus

Typical surprise -5.4% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Jul 30$7.81 vs $5.81beat
  • Thu, Feb 26$7.59 vs $5.83beat
  • Thu, Jul 31$2.88 vs $3.89miss
  • Thu, Feb 27$4.56 vs $2.68beat
  • Thu, Jul 25$1.15 vs $1.89miss
  • Wed, Feb 28$0.18 vs $1.48miss

Estimates and results for UCBJF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

Project earnings forward and see what return today's price implies.

Seeded from UCBJF's reported EPS growth of 10.0% a year over 4 years.

EPS in 5 years
$13.20
Implied price
$396.04
Return from $254.59
9.2% a year

To earn 15.0% a year on these assumptions you'd need to buy at $196.90 -22.7% below today's price.

How sensitive is that answer?

Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.

growth \ P/E2025303540
0.0%-8.4%-4.2%-0.7%2.4%5.2%
5.0%-3.8%0.5%4.3%7.5%10.4%
10.0%0.7%5.3%9.2%12.7%15.7%
15.0%5.3%10.1%14.2%17.8%21.0%
20.0%9.9%14.9%19.2%22.9%26.2%

This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.

Mentions (1)

  • Newszacks.com·4d ago·Positive

    United Community Banks (UCB) Could Be a Great Choice Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does United Community Banks (UCB) have what it takes?

    View source ↗